Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yoshiya Tanaka

Showing results (11-20 of 1,128) with videos related to

Pageof 113
Sort By:
Clinical Calcium|May 30, 2014
[Biologic agents for the treatment of rheumatic diseases]Yoshiya Tanaka
Best Practice & Research. Clinical Rheumatology|January 26, 2023
Systemic lupus erythematosusYoshiya Tanaka
Seminars in Arthritis and Rheumatism|March 2, 2025
Is mixed connective tissue disease (MCTD) a subtype of systemic sclerosis?Yoshiya Tanaka
The New England Journal of Medicine|June 3, 2026
Emerging Era for Polymyalgia Rheumatica and GCA - Interleukin-17A TargetingYoshiya Tanaka
Clinical Calcium|September 2, 2014
[Glucocorticoid and Bone. Pathogenesis of glucocorticoid-induced osteoporosis]Yoshiya Tanaka
Best Practice & Research. Clinical Rheumatology|October 8, 2025
Novel therapies in treatments of SLEYoshiya Tanaka
Expert Opinion on Biological Therapy|July 11, 2023
Ozoralizumab: first Nanobody® therapeutic for rheumatoid arthritisYoshiya Tanaka
Journal of Biochemistry|July 9, 2015
Recent progress and perspective in JAK inhibitors for rheumatoid arthritis: from bench to bedsideYoshiya Tanaka
Brain and Nerve = Shinkei Kenkyu No Shinpo|May 19, 2021
[Recent Perspectives for Targeted Therapies]Yoshiya Tanaka
Inflammation and Regeneration|January 8, 2023
A review of Janus kinase inhibitors for the treatment of Covid-19 pneumoniaYoshiya Tanaka
Pageof 113

Showing results (11-20 of 1,128) with videos related to

Sort By:
Pageof 113
Clinical Calcium|May 30, 2014
[Biologic agents for the treatment of rheumatic diseases]Yoshiya Tanaka
Best Practice & Research. Clinical Rheumatology|January 26, 2023
Systemic lupus erythematosusYoshiya Tanaka
Seminars in Arthritis and Rheumatism|March 2, 2025
Is mixed connective tissue disease (MCTD) a subtype of systemic sclerosis?Yoshiya Tanaka
The New England Journal of Medicine|June 3, 2026
Emerging Era for Polymyalgia Rheumatica and GCA - Interleukin-17A TargetingYoshiya Tanaka
Clinical Calcium|September 2, 2014
[Glucocorticoid and Bone. Pathogenesis of glucocorticoid-induced osteoporosis]Yoshiya Tanaka
Best Practice & Research. Clinical Rheumatology|October 8, 2025
Novel therapies in treatments of SLEYoshiya Tanaka
Expert Opinion on Biological Therapy|July 11, 2023
Ozoralizumab: first Nanobody® therapeutic for rheumatoid arthritisYoshiya Tanaka
Journal of Biochemistry|July 9, 2015
Recent progress and perspective in JAK inhibitors for rheumatoid arthritis: from bench to bedsideYoshiya Tanaka
Brain and Nerve = Shinkei Kenkyu No Shinpo|May 19, 2021
[Recent Perspectives for Targeted Therapies]Yoshiya Tanaka
Inflammation and Regeneration|January 8, 2023
A review of Janus kinase inhibitors for the treatment of Covid-19 pneumoniaYoshiya Tanaka
Pageof 113